Jason Bryant is Vice President, Product Management for AI & Data at ArisGlobal, based in London, UK. A Data Science Actuary, he has built his career in fintech and healthtech, and specialises in AI-powered, data-driven, yet human-centric product innovation.

Abstract

Few foresaw the impact OpenAI’s ChatGPT would have just 2.5 years ago. Yet GenAI has already begun disrupting entire industries and new technology breakthroughs are emerging at pace. As new iterations push the boundaries of deep research and insight generation, the implications for life sciences are both profound and uncertain. ArisGlobal’s Jason Bryant considers how the biopharma industry can best prepare for an undefined future that is already unfolding.

Over the last year in particular, entire industries have been caught out by Generative AI, the branch of artificial intelligence that uses everything that is known already to create something new. For a time, GenAI’s potential was constrained by the materials the technology was exposed to, then the ability to understand this in context. But with accelerating speed those limitations are being overcome.

This is giving rise to a challenging duality: the future is both already here yet still unknown. Companies must step up their preparations for profound changes which for now remain intangible.

From explanation to exploration

Next generations of GenAI are emerging almost monthly, even weekly. GenAI is now moving beyond contextual intelligence to distil and create new insight, swiftly morphing into a potential to understand and predict the previously unknowable.

From early conversational capabilities, through reasoning, the technology is already delivering ‘agentic’ capabilities (goal-driven abilities to act independently and make decisions with human intervention only w ...